1.Clinical effect of restrict rehydration strategy on anastomotic healing of patients with colorectal cancer in fast-track
Jin HAO ; Tinghan YANG ; Yi PU ; Na ZHAO ; Xiaodong WANG ; Li LI
Journal of Chinese Physician 2011;13(10):1309-1312
Objective To discuss the clinical effect of restrict rehydration strategy on anastomotic healing of patients with colorectal cancer.Methods 483 cases of colorectal cancer ( from January 2008 to November 2009) were analyzed retrospectively,166 in fluid restriction group and 317 in tradition therapy group.Postoperative early rehabilitations and complications were studied and compared.Results The first time of passing flatus(3.9 d vs 4.4 d),first ambulation(2.9 d vs 3.3 d),oral intake(2.9 d vs 3.6 d),time with use of urinary catheter(4.6 d vs 5.5 d),and drains(2.2 d vs 3.1 d),and postoperative hospital stay ( 8.7 d vs 11.6 d) in fluid restriction group were significantly earlier or less than those in tradition therapy group ( P < 0.01 ),while there were no significant differences in time with use of nasogastric tubes ( 1.1 d vs 1.2 d) between the 2 groups ( P > 0.05 ).There was significant difference in the postoperative complications rate between the two groups ( P < 0.05 ).Conclusions Restrictive fluid regimen could reduce the incidence of common complications for patients after colorectal surgery,and might have a certain promoter action to the anastomotic healing.
2.Advances in research on a novel antitumor target CDK9 and its inhibitors
Ming CHEN ; Zhouling XIE ; Tinghan LI ; Zhihui WEI ; Lu ZHAO ; Zhiyu LI
Journal of China Pharmaceutical University 2017;48(2):233-241
The cyclin-dependent protein kinase 9 (CDK9) is a member of the family of cyclin-dependent protein kinases.Different from other CDKs,CDK9 mainly works on the transcription regulation and has no affects on the cell cycle progress.There are many kinds of CDK9 inhibitors in the clinical research.The detailed structure and action mechanism of CDK9,its difference of protein structure from other CDKs,several selective or nonselective CDK9 inhibitors,as well as their structure-activity relationship (SAR) are discussed in this paper.